Phase 1 Trial Validates Anti-PD-L1 Antibody for Alzheimer’s
Summary: Researchers have reported the successful completion of a Phase 1b clinical trial of a novel immunotherapy for Alzheimer’s disease. The investigational agent, IBC-Ab002, is a humanized anti-PD-L1 monoclonal antibody designed to rejuvenate systemic immune responses rather than directly remove neurotoxic amyloid beta plaques in the brain. Key Facts Established safety profile: The Phase 1b … Read more